About the Company
An eating disorder is a mental disorder defined by abnormal eating behaviors that adversely affect a person's physical or mental health. Types of eating disorders include binge eating disorder, where the patient eats a large amount in a short period of time; anorexia nervosa, where the person has an intense fear of gaining weight and restricts food or overexercises to manage this fear; bulimia nervosa, where individuals eat a large quantity (binging) then try to rid themselves of the food (purging); pica, where the patient eats non-food items; rumination syndrome, where the patient regurgitates undigested or minimally digested food; avoidant/restrictive food intake disorder (ARFID), where people have a reduced or selective food intake due to some psychological reasons; and a group of other specified feeding or eating disorders. Anxiety disorders, depression and substance abuse are common among people with eating disorders. These disorders do not include obesity. People often experience comorbidity between an eating disorder and OCD. It is estimated 20–60% of patients with an ED have a history of OCD. The causes of eating disorders are not clear, although both biological and environmental factors appear to play a role. Cultural idealization of thinness is believed to contribute to some eating disorders. Individuals who have experienced sexual abuse are also more likely to develop eating disorders. Some disorders such as pica and rumination disorder occur more often in people with intellectual disabilities. Treatment can be effective for many eating disorders. Treatment varies by disorder and may involve counseling, dietary advice, reducing excessive exercise, and the reduction of efforts to eliminate food. Medications may be used to help with some of the associated symptoms. Hospitalization may be needed in more serious cases. About 70% of people with anorexia and 50% of people with bulimia recover within five years. Only 10% of people with eating disorders receive treatment, and of those, approximately 80% do not receive the proper care. Many are sent home weeks earlier than the recommended stay and are not provided with the necessary treatment. Recovery from binge eating disorder is less clear and estimated at 20% to 60%. Both anorexia and bulimia increase the risk of death. When people experience comorbidity with an eating disorder and OCD, certain aspects of treatment can be negatively impacted. OCD can make it harder to recover from obsession over weight and shape, body dissatisfaction, and body checking. This is in part because ED cognitions serve a similar purpose to OCD obsessions and compulsions (e.g., safety behaviors as temporary relief from anxiety). Research shows OCD does not have an impact on the BMI of patients during treatment. Estimates of the prevalence of eating disorders vary widely, reflecting differences in gender, age, and culture as well as methods used for diagnosis and measurement. In the developed world, anorexia affects about 0.4% and bulimia affects about 1.3% of young women in a given year. Binge eating disorder affects about 1.6% of women and 0.8% of men in a given year. According to one analysis, the percent of women who will have anorexia at some point in their lives may be up to 4%, or up to 2% for bulimia and binge eating disorders. Rates of eating disorders appear to be lower in less developed countries. Anorexia and bulimia occur nearly ten times more often in females than males. The typical onset of eating disorders is in late childhood to early adulthood. Rates of other eating disorders are not clear.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IGMS News
What 5 Analyst Ratings Have To Say About IGM Biosciences
In the last three months, 5 analysts have published ratings on IGM Biosciences (NASDAQ:IGMS), offering a diverse range of ...
IGM Biosciences Insiders Placed Bullish Bets Worth US$992.2k
Over the last three months, we've seen significant insider selling at IGM Biosciences. Specifically, insiders ditched US$282k ...
Big drugmaker's cancer rollback trickles down to another Bay Area company
It said in a Securities and Exchange Commission filing earlier this year that it would continue to focus on cancer and ...
IGM Biosciences Inc (IGMS) Stock: Understanding the Volatility
The stock of IGM Biosciences Inc (IGMS) has gone up by 4.57% for the week, with a -7.94% drop in the past month and a -16.42% drop in the past quarter. The volatility ratio for the week is 7.53%, and ...
IGM Biosciences Announces Refocusing of Sanofi Collaboration
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration ...
IGM and Sanofi collaboration will pivot to immunology and inflammation
I GM Biosciences has announced that the focus of its exclusive worldwide collaboration agreement with Sanofi will now shift ...
Global Injectable Drugs Industry is projected to increase at a 5.8% CAGR and reach US$9,91,631.3 Million By 2034 | FMI Report
The Global Injectable Drugs Industry is poised for significant growth, reaching an impressive US$9,91,631.3 million by 2034, ...
Non-Hodgkin Lymphoma Pipeline Landscape 2024: Analysis of Over 220 Potential Pharmaceuticals in Development
Hodgkin Lymphoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A new comprehensive report has emerged, offering in-depth insights into the future of Non-Hodgkin ...
IGM Biosciences, Inc.: IGM Biosciences Announces Refocusing of Sanofi Collaboration
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
Loading the latest forecasts...